Related references
Note: Only part of the references are listed.Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
Simon J. Bowman et al.
LANCET (2022)
A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
Jack Arnold et al.
FRONTIERS IN IMMUNOLOGY (2022)
Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab
Jack Arnold et al.
RHEUMATOLOGY (2022)
A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
Jack Arnold et al.
FRONTIERS IN IMMUNOLOGY (2022)
COVID-19 vaccination and antirheumatic therapy
Jack Arnold et al.
RHEUMATOLOGY (2021)
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
Daniel Mrak et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
NKp30 Receptor Upregulation in Salivary Glands of Sjogren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment
Elena Pontarini et al.
FRONTIERS IN IMMUNOLOGY (2021)
Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy
Alice Combier et al.
RHEUMATOLOGY (2020)
Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab
Sabih Ul Hassan et al.
FRONTIERS IN MEDICINE (2020)
Abatacept treatment for patients with early active primary Sjogren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)
Jolien F. van Nimwegen et al.
LANCET RHEUMATOLOGY (2020)
Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus
Chris Wincup et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases
Md Yuzaiful Md Yusof et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Symptom-based stratification of patients with primary Sjogren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials
Jessica R. Tarn et al.
LANCET RHEUMATOLOGY (2019)
B cells in the pathogenesis of primary Sjogren syndrome
Gaetane Nocturne et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab
Sherry Masoud et al.
RHEUMATOLOGY (2018)
Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjogren's syndrome
Gwenny M. Verstappen et al.
RHEUMATOLOGY (2018)
Effect of rituximab on a salivary gland ultrasound score in primary Sjogren's syndrome: results of the TRACTISS randomised double- blind multicentre substudy
Benjamin A. Fisher et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjogren's Syndrome
Simon J. Bowman et al.
ARTHRITIS & RHEUMATOLOGY (2017)
The value of rituximab treatment in primary Sjogren's syndrome
Gwenny M. Verstappen et al.
CLINICAL IMMUNOLOGY (2017)
Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus
Md Yuzaiful Md Yusof et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series
Stephen P. McAdoo et al.
RHEUMATOLOGY (2016)
Defining disease activity states and clinically meaningful improvement in primary Sjogren's syndrome with EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)
Raphaele Seror et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions
Md Yuzaiful Md Yusof et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years
Ronald F. van Vollenhoven et al.
JOURNAL OF RHEUMATOLOGY (2015)
How to develop a more accurate risk prediction model when there are few events
Menelaos Pavlou et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNFα Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients
Inesa Arstikyte et al.
BIOMED RESEARCH INTERNATIONAL (2015)
How to develop a more accurate risk prediction model when there are few events
Menelaos Pavlou et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjogren's Syndrome
Sandrine Jousse-Joulin et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Responses to Rituximab Suggest B Cell-Independent Inflammation in Cutaneous Systemic Lupus Erythematosus
Edward M. Vital et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology
Maya H. Buch et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial
Edward M. Vital et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide
Raphaele Seror et al.
RMD OPEN (2015)
Treatment of Primary Sjogren Syndrome With Rituximab A Randomized Trial
Valerie Devauchelle-Pensec et al.
ANNALS OF INTERNAL MEDICINE (2014)
Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis
Yan Liang et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis
Emilio Besada et al.
RHEUMATOLOGY (2014)
Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0
Tatiana Cobo-Ibanez et al.
RHEUMATOLOGY INTERNATIONAL (2014)
Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry
Jacques-Eric Gottenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Rituximab Therapy for Primary Sjogren's Syndrome: An Open-Label Clinical Trial and Mechanistic Analysis
E. William St Clair et al.
ARTHRITIS AND RHEUMATISM (2013)
Longterm Effects of Rituximab on B Cell Counts and Autoantibody Production in Rheumatoid Arthritis: Use of High-sensitivity Flow Cytometry for More Sensitive Assessment of B Cell Depletion
Andrea Vancsa et al.
JOURNAL OF RHEUMATOLOGY (2013)
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
Chamaida Plasencia et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study
Francesco Carubbi et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab
A. Ruyssen-Witrand et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren's syndrome treated with rituximab
P. M. Meiners et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study
Alf Kastbom et al.
BMJ OPEN (2012)
B Cell Biomarkers of Rituximab Responses in Systemic Lupus Erythematosus
Edward M. Vital et al.
ARTHRITIS AND RHEUMATISM (2011)
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
Hans-Peter Tony et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome
Raphaele Seror et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Effectiveness of Rituximab Treatment in Primary Sjogren's Syndrome A Randomized, Double-Blind, Placebo-Controlled Trial
J. M. Meijer et al.
ARTHRITIS AND RHEUMATISM (2010)
Management of Nonresponse to Rituximab in Rheumatoid Arthritis Predictors and Outcome of Re-treatment
E. M. Vital et al.
ARTHRITIS AND RHEUMATISM (2010)
Risk Factors for Severe Infections in Patients With Rheumatoid Arthritis Treated With Rituximab in the AutoImmunity and Rituximab Registry
J. -E. Gottenberg et al.
ARTHRITIS AND RHEUMATISM (2010)
Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study
S. Dass et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Highly Sensitive B Cell Analysis Predicts Response to Rituximab Therapy in Rheumatoid Arthritis
Shouvik Dass et al.
ARTHRITIS AND RHEUMATISM (2008)
Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20)
Valerie Devauchelle-Pensec et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Rituximab treatment in patients with primary Sjogren's syndrome
J Pijpe et al.
ARTHRITIS AND RHEUMATISM (2005)
Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group
C Vitali et al.
ANNALS OF THE RHEUMATIC DISEASES (2002)
Share Paper
